Back to Search
Start Over
Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review
- Source :
- Case Reports in Oncology, Vol 17, Iss 1, Pp 1063-1069 (2024)
- Publication Year :
- 2024
- Publisher :
- Karger Publishers, 2024.
-
Abstract
- Introduction: Multiple myeloma represents a malignant disorder of plasma cells. Extramedullary relapse in multiple myeloma is a rare occurrence, and pericardial involvement stands as an exceedingly uncommon manifestation. Only a few documented cases of pericardial effusion as an extramedullary relapse presentation of myeloma exist. Bispecific antibodies are emerging as a novel class of immunotherapy drugs for the treatment of relapsed refractory multiple myeloma patients who have experienced failure with four prior lines of therapy. According to a literature review, none of the reported cases with pericardial effusion relapsed myeloma have been treated with bispecific antibodies, given that these drugs have only recently gained approval. Case Presentation: We present a rare case of a patient with pericardial effusion resulting from myeloma relapse, treated with teclistamab, a bispecific antibody, and achieving an excellent response. Conclusion: Bispecific antibodies, such as teclistamab, show great effectiveness as a treatment for patients with relapsed refractory multiple myeloma, including those with extramedullary disease.
Details
- Language :
- English
- ISSN :
- 16626575, 00054097, and 44352999
- Volume :
- 17
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Case Reports in Oncology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.74a44352999c464fb6f1d6ca9e4c069f
- Document Type :
- article
- Full Text :
- https://doi.org/10.1159/000540979